{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:06:21Z","timestamp":1791187581440,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T00:00:00Z","timestamp":1325116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As a result of shared modes of transmission, chronic hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> infection is common in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients, particularly among those who have used injection drugs as well as men who have sex with men (<jats:styled-content style=\"fixed-case\">MSM<\/jats:styled-content>s). In the era of effective antiretroviral therapy, <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection has emerged as a major cause of morbidity and mortality worldwide. Over the last decade, treatment with peginterferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) plus ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment in this population has been disappointing. Challenges to the use of <jats:styled-content style=\"fixed-case\">HCV NS<\/jats:styled-content>3\/<jats:styled-content style=\"fixed-case\">4A<\/jats:styled-content> protease inhibitors, telaprevir and boceprevir, patients with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> coinfection include the potential for interactions between different drugs, addition of drug toxicities, and the need for therapy with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>. Despite these challenges, limited data indicate that telaprevir and boceprevir given in combination with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> increase the rate of viral suppression in coinfected patients with manageable toxicity and drug\u2010drug interaction profile. Accordingly, these agents may be recommended for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment in carefully selected <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected persons.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2011.02719.x","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T17:38:09Z","timestamp":1325180289000},"page":"129-134","source":"Crossref","is-referenced-by-count":20,"title":["Hepatitis <scp>C<\/scp> virus\u2010human immunodeficiency virus coinfection"],"prefix":"10.1111","volume":"32","author":[{"given":"Mark S.","family":"Sulkowski","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a0918"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.726"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01229.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832e5631"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.053"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.11.018"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21990"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-007-9083-3"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32801086da"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.081906.081110"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/520144"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/339042"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.199"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/656212"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21173"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.006"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281053a0c"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.224"},{"key":"e_1_2_8_20_1","first-page":"602","article-title":"Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study","volume":"6","author":"Eyster ME","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/321909"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14844-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.07.006"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f6d916"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.08.004"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e6d51"},{"key":"e_1_2_8_27_1","unstructured":"PEGASYS (peginterferon alfa\u20102a) Prescribing Information. Revised March 2010.Nutley NJ:Hoffman\u2010La Roche Inc. 2010."},{"key":"e_1_2_8_28_1","unstructured":"PEGINTRON (peginterferon alfa\u20102b) Prescribing Information. Revised January 2010.Kenilworth NJ:Schering Corporation 2010."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"e_1_2_8_31_1","unstructured":"Rodriguez\u2010TorresM LeaSJB.Standard versus high dose ribavirin in combination with peginterferon alfa\u20102a in genotype 1 HCV patients coinfected with HIV: final results of the PARADIGM study[Abstract]. Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases.Boston MA USA 2009Nov 3; Abstract 1561."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00824.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032653"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.23.2839"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409030-00003"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0011"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22598"},{"key":"e_1_2_8_38_1","unstructured":"SulkowskiMS KeaDDDKS.Interim Analysis of a Phase 2a Double\u2010blind Study of TVR in Combination with pegIFN\u2010a2a and RBV in HIV\/HCV Co\u2010infected Patients[Abstract]. 18th Conference on Retroviruses and Opportunistic Infections.Boston MA USA 2011Mar 2; Abstract 146LB."},{"key":"e_1_2_8_39_1","unstructured":"SulkowskiMS ea.Boceprevir plus peginterferon\/ribavirin for the treatment of HCV\/HIV co\u2010infected patients[Abstract]. Infectious Diseases Society of America Meeting.Boston MA USA 2011 Oct 22; Abstract LB\u201037."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq086"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2011.02719.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2011.02719.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T19:33:58Z","timestamp":1694460838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2011.02719.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,29]]},"references-count":39,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1478-3231.2011.02719.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02719.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,29]]}}}